Genovis
Genovis develops and supplies proprietary SmartEnzymes used to identify and characterize antibody-based biotherapeutics, including monoclonal antibodies, ADCs, and biosimilars, serving biotech and pharmaceutical R&D and QC customers.
- Company typePrivate
- Founded1999
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Genovis does
Genovis is a biotechnology company that develops and supplies "SmartEnzymes" used to identify and characterize antibody-based biotherapeutics, including monoclonal antibodies, antibody-drug conjugates (ADCs), and biosimilars. Founded in 1999, the company operates with a small team (11-50 employees) and is listed as headquartered in Cambridge per available source data, with financial reporting denominated in Swedish kronor. Following an August 2024 strategic divestment of its antibody business to Leinco Technologies, Genovis has refocused its operations on its core enzyme technology segment serving biotech and pharmaceutical R&D and quality-control customers.
The company pursues a horizontal segmentation approach built around a single primary segment, Enzyme Operations, with no product-level architectural details publicly disclosed in the source material. Its go-to-market centers on proprietary enzyme reagents embedded in customer analytical workflows, and its revenue mechanics are not transparently disclosed (no pricing model, no publicly disclosed prices, and no named customers). Strategic activity under CEO Fredrik Olsson has emphasized portfolio reshaping: the 2024 antibody-business divestment, the 2020 acquisition of QED Bioscience, and the announced 2026 acquisition of KPL, indicating an M&A-driven approach to extending the company's specialty reagents footprint beyond its core enzyme offering.
No AI/ML capabilities, app products, public-company listing status, or detailed ownership structure are evidenced in the available source material. Customer logos, geographic split, and total revenue figures are also not disclosed, and the multi-year financial dataset appears corrupted (figures in the trillions), limiting quantitative triangulation of scale.
Genovis firmographics
Firmographics- Name
- Genovis
- Website
- https://genovis.com
- Company type
- Private
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Genovis develops and supplies proprietary SmartEnzymes used to identify and characterize antibody-based biotherapeutics, including monoclonal antibodies, ADCs, and biosimilars, serving biotech and pharmaceutical R&D and QC customers.
- Ownership category
- akta.pro rank
Genovis industry classification
Industry- Product category
- Biotechnology Reagents
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
- akta.pro secondary industries
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)
Keywords
Where Genovis is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
Genovis business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Genovis product offering
Product offeringCore offering
Genovis develops and sells SmartEnzymes, proprietary enzyme reagents used by biopharmaceutical researchers to identify and characterize antibody-based biotherapeutics, including monoclonal antibodies, antibody-drug conjugates (ADCs), and biosimilars. Following its August 2024 divestment of its antibody business to Leinco Technologies, the company has refocused exclusively on its core enzyme product line for the biotech and pharmaceutical markets.
Product overview
Genovis is a biotechnology company that, following the strategic divestment of its antibody business to Leinco Technologies in August 2024, has refocused its operations on core enzyme products. The available source material does not provide specific product names, product architecture details, or product portfolio listings.
Differentiator
Problem solved
Functional benefit
Products and services
- SmartEnzymes
Companies that use Genovis
Customer profileSegments1 record
Ideal customer profiles1 record
Genovis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Genovis partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Leinco Technologies Inc.majorGenovis divested its antibody business to Leinco Technologies Inc. This strategic divestment allows Genovis to focus exclusively on its core enzyme operations. The transaction is intended to enhance profitability and foster growth in the company's primary market segment of enzyme technology.
Scale indicators1 record
Recent moves5 records
Expansion highlights3 records
Genovis competitors and assessment
Company assessmentDirect peers
- New England Biolabs (NEB): NEB is a leading developer and manufacturer of enzymes for molecular biology and protein research, including glycosidases and proteases used to characterize biologics. It is a direct peer to Genovis because both sell engineered enzymes into the same biopharma characterization and protein engineering workflows.
- Promega Corporation: Promega supplies enzymes, reagents, and integrated kits used in protein analysis, biologics characterization, and drug development. It is comparable to Genovis because it sells similar enzyme-based tools to biopharma R&D and QC labs, particularly for antibody and protein characterization.
Broad incumbents
- Bio-Techne: Bio-Techne is a large life-sciences tools company with a deep portfolio of proteases, reagents, and antibodies used in biologics development and quality control. It is comparable as a broad incumbent whose protein and enzyme reagents overlap directly with Genovis's SmartEnzymes in mAb/ADC/biosimilar workflows.
- Thermo Fisher Scientific: Thermo Fisher's Life Sciences Solutions and bioscience reagents businesses sell enzymes, antibodies, and characterization tools across the biopharma value chain. It is a broad incumbent comparable to Genovis because it overlaps in enzymes and biologics characterization, although at vastly greater scale.
- Sartorius AG: Sartorius supplies bioprocessing equipment, consumables, and analytical tools used in upstream and downstream biologics manufacturing, including QC. It is comparable to Genovis because biopharma manufacturers often purchase both Sartorius bioprocess tools and Genovis-style characterization enzymes as part of the same workflow.
- Cytiva (Danaher): Cytiva supplies resins, columns, instruments, and analytical consumables for bioprocessing and biologics QC. It is comparable as a broad incumbent that touches the same antibody/biosimilar manufacturing and characterization workflows as Genovis's enzyme products.
- Waters Corporation: Waters supplies chromatography systems, columns, and software used in protein and biologics characterization, including for mAbs, ADCs, and biosimilars. It is comparable to Genovis because its analytical instruments and consumables address the same characterization workflow that Genovis enzymes support.
- Agilent Technologies: Agilent provides analytical instruments, columns, and reagents for protein characterization, biopharma QC, and biosimilar analysis. It is comparable as a broad incumbent with overlapping tools in the biologics characterization workflow where Genovis's SmartEnzymes are used.
- Roche Diagnostics: Roche Diagnostics sells a broad portfolio of clinical chemistry, immunoassay, and biopharma testing products used in protein and antibody analysis. It is a broad incumbent comparable to Genovis because its CustomBiotech and diagnostics businesses supply tools and reagents to biopharma characterization workflows alongside Genovis's SmartEnzymes.
Emerging players
- Codexis: Codexis engineers novel enzymes and biocatalysts using directed-evolution platforms for pharmaceutical and biopharma applications. It is an emerging player comparable to Genovis because both companies commercialize engineered enzymes for therapeutic and biologics-related applications, though Codexis leans more into biocatalysis for synthesis while Genovis focuses on characterization.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Genovis social profiles
Digital presenceGenovis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genovis leadership team
Management profileNumber of profiles
Profiles1 record
Genovis funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genovis M&A and investment
M&A and investmentM&A2 records
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genovis
What does Genovis do?
Genovis develops and sells SmartEnzymes, proprietary enzyme reagents used by biopharmaceutical researchers to identify and characterize antibody-based biotherapeutics, including monoclonal antibodies, antibody-drug conjugates (ADCs), and biosimilars. Following its August 2024 divestment of its antibody business to Leinco Technologies, the company has refocused exclusively on its core enzyme product line for the biotech and pharmaceutical markets.
When was Genovis founded?
Genovis was founded in 1999. It employs 11 to 50 people.
Where is Genovis based?
Genovis is headquartered in Cambridge, United States, in the North America region.
Who are Genovis's main competitors?
Direct peers on record are New England Biolabs (NEB) and Promega Corporation. Broad incumbents are Bio-Techne, Thermo Fisher Scientific, Sartorius AG, Cytiva (Danaher), Waters Corporation, Agilent Technologies and Roche Diagnostics. Codexis is listed as an emerging player.
Does Genovis have an API?
No public API is recorded for Genovis.
What industry is Genovis in?
Genovis's product category is Biotechnology Reagents. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 325414 and its SIC code is 2836.